Pfizer Inc. (NYSE: PFE) today announced the U.S. Food and Drug Administration (FDA) approved IBRANCEÂ (palbociclib) in combination with trastuzumab, with or w

MasterBrand, Inc. (MBC) stock price & volume — 10-year historical chart
Investment Thesis • Updated 2026Q1
highlighted by a -23.7% free cash flow margin and a net loss of $15.4 million in 2026Q1, suggests significant downside risk in the current housing cycle.
MasterBrand, Inc. (MBC) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
MasterBrand, Inc. (MBC) EPS & revenue vs analyst estimates — last 4 quarters
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 5, 2026 | $0.06vs $0.04+271.4% | $618Mvs $591M+4.5% |
| Q1 2026 | Feb 10, 2026 | $0.02vs $0.14-114.3% | $645Mvs $608M+6.1% |
| Q4 2025 | Nov 4, 2025 | $0.33vs $0.14+135.7% | $699Mvs $608M+15.0% |
| Q3 2025 | Aug 6, 2025 | $0.40vs $0.38+5.3% | $731Mvs $693M+5.5% |
Recent stock market news and headlines for MasterBrand, Inc. (MBC)
Pfizer Inc. (NYSE: PFE) today announced the U.S. Food and Drug Administration (FDA) approved IBRANCEÂ (palbociclib) in combination with trastuzumab, with or w

Key metrics vs top competitors for MasterBrand, Inc. (MBC)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $9.02 | $1.15B | 42.95 | 1.27% | 0.98% | 2.02% | — | |
| $112.88 | $6.91B | 19.04 | -0.48% | 3.77% | 4.96% | — | |
| $48.09 | $700.65M | 7.40 | -7.47% | 1.15% | 1.91% | — | |
| $47.11 | $4.89B | 26.47 | 1.98% | 16.25% | 18.85% | — | |
| $1.25 | $107.88M | -0.17 | -14.95% | -16.09% | -291.23% | — | |
| $155.36 | $6.63B | 21.94 | 12.11% | 18.59% | 34.81% | — |
MasterBrand, Inc. (MBC) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
MasterBrand, Inc. (MBC) SEC filings — annual & quarterly reports (10-K, 10-Q)
May 5, 2026·SEC
Apr 22, 2026·SEC
Mar 26, 2026·SEC
Get notified when MBC posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
MasterBrand, Inc. (MBC) stock FAQ — growth, dividends, profitability & financials explained
MasterBrand, Inc. (MBC) reported $2.69B in revenue for fiscal year 2025. This represents a 9% increase from $2.47B in 2020.
MasterBrand, Inc. (MBC) grew revenue by 1.3% over the past year. Growth has been modest.
MasterBrand, Inc. (MBC) reported a net loss of $2.0M for fiscal year 2025.
MasterBrand, Inc. (MBC) has a return on equity (ROE) of 2.0%. This is below average, suggesting room for improvement.
MasterBrand, Inc. (MBC) generated $12.5M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.